Cargando…

Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab

IMPORTANCE: Consolidative durvalumab after definitive chemoradiation for unresectable locally advanced non–small cell lung cancer (NSCLC) can significantly improve progression-free survival (PFS) and overall survival (OS), as shown in the PACIFIC trial. However, whether patients with driver variatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yufei, Zhang, Zhe, Rinsurongkawong, Waree, Gay, Carl M., Le, Xiuning, Ning, Matthew S., Lewis, Jeff, Rinsurongkawong, Vadeerat, Lee, J. Jack, Roth, Jack, Swisher, Stephen, Gandhi, Saumil, Lee, Percy P., Gibbons, Don L., Vaporciyan, Ara A., Heymach, John V., Zhang, Jianjun, Lin, Steven H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171557/ https://www.ncbi.nlm.nih.gov/pubmed/35666500 http://dx.doi.org/10.1001/jamanetworkopen.2022.15589

Ejemplares similares

Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival
por: De, Brian, et al.
Publicado: (2023)

ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC
por: Vokes, Natalie I., et al.
Publicado: (2023)

Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
por: Hong, Lingzhi, et al.
Publicado: (2023)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Lewis, Whitney E., et al.
Publicado: (2021)

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
por: Altan, Mehmet, et al.
Publicado: (2023)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
por: Saad, Maliazurina B, et al.
Publicado: (2023)

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
por: Langberg, Christian Wilhelm, et al.
Publicado: (2023)

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
por: Negrao, Marcelo V, et al.
Publicado: (2021)

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
por: Hong, Lingzhi, et al.
Publicado: (2022)

Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer
por: Chu, Chia‐Hsun, et al.
Publicado: (2020)

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
por: Diamond, Brett H., et al.
Publicado: (2022)

MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
por: Alhalabi, Omar, et al.
Publicado: (2022)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
por: Shaverdian, Narek, et al.
Publicado: (2020)

Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy
por: Nam, Jung Hyun, et al.
Publicado: (2023)

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study
por: Wang, Chin-Chou, et al.
Publicado: (2021)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Sarcoid-Like Granulomatosis of the Lung Related to Durvalumab After Chemoradiation for Pulmonary Squamous Cell Carcinoma
por: Minami, Seigo, et al.
Publicado: (2023)

Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling
por: Tran, Hai T., et al.
Publicado: (2021)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies
por: Zhang, Yatong, et al.
Publicado: (2023)

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
por: Moodie, Travis, et al.
Publicado: (2022)

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
por: Preti, Beatrice T. B., et al.
Publicado: (2023)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy
por: Pataer, Apar, et al.
Publicado: (2022)

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer
por: Hong, Lingzhi, et al.
Publicado: (2021)

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone
por: Saad, Akram, et al.
Publicado: (2022)

Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches
por: Parra, Edwin R., et al.
Publicado: (2018)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy
por: Pataer, Apar, et al.
Publicado: (2018)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study
por: Li, Yuanming, et al.
Publicado: (2022)

Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab
por: Nindra, Udit, et al.
Publicado: (2022)

Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer
por: Kawai, Shoko, et al.
Publicado: (2020)

Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report
por: Masuda, Kosuke, et al.
Publicado: (2023)

Genetic variation in the TNF/TRAF2/ASK1/p38 kinase signaling pathway as markers for postoperative pulmonary complications in lung cancer patients
por: Hildebrandt, Michelle A. T., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0f171cbfum2umfsgqeh4206hqa